Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0174
Source ID: NCT02885857
Associated Drug: Shenyan Kangfu Tablet
Title: Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Chronic Kidney Disease
Interventions: DRUG: Shenyan Kangfu Tablet
Outcome Measures: Primary: 24-hour urinary protein excretion, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times | Secondary: Serum creatinine, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Glomerular filtration rate, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Albumin, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Glycated hemoglobin, Observations of the project value and the percentage change in value before and after the treatment., Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times|Symptom scores, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times | Other: Routine blood test, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Routine urine test, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Liver function, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Renal function tests, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Potassium detection, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|blood glucose testing, Observation time: 24 weeks.Tested once every 12 weeks, it was detected three times|Electrocardiograph, Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times|chest radiography, Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times|Adverse events / adverse reactions, Follow-up 3 times.Subject at any time to contact your doctor., Observation time: 24 weeks.Tested once every 24 weeks, were detected in 2 times
Sponsor/Collaborators: Sponsor: Chen Xiangmei | Collaborators: Tianjin TongRenTang Group Co., Ltd.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 1500
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2015-06
Completion Date: 2016-12
Results First Posted:
Last Update Posted: 2016-09-01
Locations: National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital, Beijing, Beijing, 100853, China|Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China|Daping Hospital,Research Institute of Surgery Third Military Medical University, Chongqing, Chongqing, China|Fuzhou General Hospital Nanjing Military Command, Fuzhou, Fujian, China|174th hospital of the People's Liberation Army, Xiamen, Fujian, China|Beidaihe Sanatorium of Beijing Military Mrca, Qinhuangdao, Hebei, China|Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China|Henan Provincial People'S Hospital, Zhengzhou, Henan, China|Shandong Province Hospital, Jinan, Shandong, China|Changhai Hospital of Shanghai, Shanghai, Shanghai, China|LONGHUA Hospital Shanghai University of TCM, Shanghai, Shanghai, China|First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|First Teaching Hospital of Tianjin University of TCM, Tianjin, Tianjin, China
URL: https://clinicaltrials.gov/show/NCT02885857